The head of the department is hematologist, Anastasia V. Abramova, Candidate of Medical Sciences.
The department was formed in October 2018. From 2018 to 2021, the department was headed by Candidate of Medical Sciences, Zalina T. Fidarova, from 2022 — Candidate of Medical Sciences, doctor of the first category, Irina A. Lukyanova.
The department, together with the Department of Hemoblastosis and Hematopoietic Depression Chemotherapy with Bone Marrow and Hematopoietic Stem Cell Transplantation Unit, is developing a scientifically based approach to the treatment of leukemia, myelodysplastic syndromes, aplastic anemia, as well as creating new treatment programs and introducing them into wide-ranging hematology practice. All stages of hemoblastosis therapy are performed in the department: from induction to maintenance treatment; replacement hemotransfusion therapy; immunosuppressive therapy of patients with aplastic anemia; dispensary observation of patients who have completed program therapy.
The staff of the department are highly qualified experts in the field of leukemia and hematopoietic depressions. They participate in all conferences "Leukemias and lymphomas. Therapy and Fundamental Research" conducted by the NMRC for Hematology, send abstracts and take part in annual international and domestic conferences on hematology. They are organizers, experts and participants of Russian congresses on hematology and present the results of their scientific and clinical developments at many regional conferences across Russia.
